Biomarker ID | 20 |
PMID | 14654526 |
Year | 2003 |
Biomarker | CGA |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated in PCa(atleast 2 fold) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Peptide hormone biosynthesis,Hormone ligand-binding G-protein coupled receptors,Amine-derived hormones,Androgen biosynthesis,Thyroxine biosynthesis |
Experiment | Normal Prostate vs Prostate Cancer |
Type of Biomarker | Diagnostic |
Cohort | 14 patients with prostate cancer and 7 normal prostates were included for analysis |
Senstivity | NA |
Specificity | NA |
AUC | 0.143 |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | qRT-PCR |
Clinical | No |
Remarks | Out of 291 genes, 46 genes showed differential expression, out of which a 4 gene panel was selected to differentiate b/w the patients who relapsed and those who did not. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | CGA |